Trial Profile

A Multinational, Multicenter, Open-Label Phase II Study of SyB L-0501 in Combination With Rituximab in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Nov 2019 According to a SymBio Pharmaceuticals media release, based on the favorable clinical results from this study BR therapy has been recommended in the National Comprehensive Cancer Network (NCCN) Guidelines in the UnitedStates since 2012.
10 Feb 2015 According to a SymBio Pharmaceuticals media release, this phase II trial generated positive data. The company will continue to pursue approval for refractory/relapsed intermediate/high-grade non-Hodgkin's lymphoma.
01 Jun 2012 Resutls presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a SymBio Pharmaceuticals media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com